Drugs / TCR1020-CD8 T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06707896 | Jun 2025 → Feb 2029 | colorectal cancer, pancreatic adenocarcinoma | University of Pennsylvania | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCR1020-CD8 T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06707896 ↗ |
| Modality | Cell therapy | “autologous mKRAS-redirected CD8+ T cells” NCT06707896 ↗ |
| Target | KRAS | “specificity for HLA-restricted mKRAS G12V epitopes” NCT06707896 ↗ |